Q32 Bio Inc. — Director's Dealing 2021

Feb 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2021-02-01

Reporting Person: Kelly Timothy P (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-01	Common Stock	M	2000	$6.6314	Acquired	2000	Direct
2021-02-01	Common Stock	M	2000	$2.8947	Acquired	4000	Direct
2021-02-01	Common Stock	S	4000	$12.365	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-01	Employee Stock Options	$6.6314	M	2000	Disposed	2027-12-06	Common Stock (2000)	Direct
2021-02-01	Employee Stock Options	$2.8947	M	2000	Disposed	2027-09-06	Common Stock (2000)	Direct

Footnotes

F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.

F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.13 to $12.3680. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018, so that such option will become fully vested on January 1, 2022.

F4: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was May 30, 2017.